论文部分内容阅读
目的:观察并比较中、重度癌痛患者服用盐酸羟考酮控释片与硫酸吗啡缓释片后疼痛缓解情况及生存质量的改善。方法:将60例中、重度癌痛患者1∶1分为2组,A组给予盐酸羟考酮控释片治疗,B组给予硫酸吗啡缓/控释片治疗,均规律服药14d后评定疼痛缓解度并评估患者的生存质量、记录不良反应。结果:2组患者疼痛程度均较治疗前显著减轻(P<0.05),总有效率分别为96.7%和93.3%,2组比较差异无统计学意义(P>0.05),但A组镇痛起效较B组快(P<0.01)。2组患者治疗后生存质量明显改善,但差异无统计学意义(P>0.05)。2组不良反应主要为便秘、头晕、恶心、呕吐、嗜睡等,且A组便秘明显较轻(P<0.01),其他不良反应比较差异无统计学意义(P>0.05)。结论:盐酸羟考酮控释片与硫酸吗啡缓/控释片治疗中、重度癌痛镇痛效果相近,服用安全,且羟考酮控释片起效快,便秘较轻,可作为中、重度癌痛治疗的首选药物之一。
OBJECTIVE: To observe and compare the pain relief and quality of life of patients with moderate and severe cancer pain after taking oxycodone hydrochloride controlled release tablets and morphine sustained release tablets. Methods: Sixty patients with moderate and severe cancer pain were divided into two groups at 1: 1, group A received oxycodone hydrochloride controlled release tablets, and group B received morphine phosphate controlled / controlled release tablets. All patients were given regular pain for 14 days To assess the patient’s quality of life and adverse reactions. Results: The pain scores in both groups were significantly lower than those before treatment (P <0.05), and the total effective rates were 96.7% and 93.3% respectively. There was no significant difference between the two groups (P> 0.05) Effective than the B group (P <0.01). The quality of life of the two groups improved significantly after treatment, but the difference was not statistically significant (P> 0.05). The adverse reactions of the two groups were mainly constipation, dizziness, nausea, vomiting and drowsiness, and the constipation in group A was significantly lighter (P <0.01). There was no significant difference in other adverse reactions (P> 0.05). Conclusion: Oxycodone hydrochloride controlled-release tablets and morphine mild / controlled release tablets in the treatment of moderate and severe analgesic analgesic effect is similar, taking safe, and oxycodone controlled release tablets rapid onset, less constipation, can be used as a medium, Severe cancer pain treatment of choice of drugs.